MALVERN, Pennsylvania, December 21 /PRNewswire/ --
Solstice Neurosciences, Inc. ("Solstice") announced the appointment of Dennis L. Smith as President and Chief Executive Officer. He will also continue to serve as Chairman to its Board of Directors.
Mr. Smith brings unique specialty pharmaceutical industry experience and expertise to Solstice that will be invaluable in providing guidance, leadership, and strategies for growth as the company continues to broaden its product portfolio globally and map its strategy.
Mr. Smith has nearly 35 years of broad and global experience in the pharmaceutical industry and most recently served as President and Chief Executive Officer of INO Therapeutics LLC., a specialty pharmaceutical company with strengths in development, marketing, and sales of critical care drugs and drug/device combinations. Prior to INO, Mr. Smith spent 15 years with DuPont Pharmaceutical Company, where he served as President of U.S. Operations, Executive Vice President of Europe, and Vice President and General Manager in Canada, among numerous other positions at DuPont Pharmaceuticals and DuPont Merck. Mr. Smith was also employed in management positions at Baxter International and Sandoz Pharmaceuticals (now Novartis). Mr. Smith is a graduate of Michigan State University and the Lake Forest Graduate School of Business.
"I am excited to be joining Solstice at this time to work with the management team and the Board of Directors to help lead and guide our company's future strategic direction," said Mr. Smith.
About Solstice Neurosciences, Inc.
Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. Solstice's first product, Myobloc(R) (Botulinum Toxin Type B) Injectable Solution, represents the only botulinum toxin type B currently available to physicians and patients. MYOBLOC is sold in the United States and approved in Canada. It is also distributed and sold in the EU as NeuroBloc. MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. For more information about Solstice Neurosciences, Inc., visit www.solsticeneuro.com.
Myobloc(R) and NeuroBloc(R) are registered trademarks of Solstice Neurosciences, Inc.
Web site: http://www.solsticeneuro.com
Mike Pagnotta of Solstice Neurosciences, Inc., +1-866-220-5042, firstname.lastname@example.org